Cellebrite under securities investigation after ARR miss and CEO change
Aug 31, 2026, 10:08 AM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting
The combination of ARR miss, guidance cut, a sudden CEO change, and a pending securities investigation creates a multi-factor overhang likely to keep CLBT under short-term pressure, as seen by the 29% intraday/close drop following the news. Historical parallels show downside risk rises when legal actions align with miss/exec changes, though ultimate outcomes depend on investigation findings and revised disclosures.
AI summary
What happened, with direct paths to the underlying reporting
Cellebrite reported Q2 ARR of $507.8 million, below the lower guidance, and cut full-year ARR guidance by about $15 million. The company also announced an abrupt CEO transition from Tom Hogan to Shiv Ramji. Separately, Kaplan Fox launched a securities investigation, contributing to near-term investor concern and a 29% stock drop to $10.80, highlighting potential governance and execution risks ahead.
Kaplan Fox launches securities investigation into CLBT. ARR miss and CEO change noted.
Q2 ARR $507.8M, below guidance.
Guidance cut midpoint by about $15M; cloud deals delayed due to foreign permit.
CEO Tom Hogan replaced by Shiv Ramji, effective immediately.
Stock fell 29% to $10.80 on Aug 13, 2026.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
- Cellebrite DI Ltd. beat earnings estimates with $0.08 per share, a 33.33% surprise. - Revenues for the quarter reached $89.58 million, exceeding estimates by 4.15%. - Recent sto…
